» Articles » PMID: 22289054

How Many Life Years Are Lost in Patients with Rheumatoid Arthritis? Secular Cause-specific and All-cause Mortality in Rheumatoid Arthritis, and Their Predictors in a Long-term Australian Cohort Study

Overview
Journal Intern Med J
Specialty General Medicine
Date 2012 Feb 1
PMID 22289054
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There is an excess of mortality in patients with rheumatoid arthritis (RA) but no long-term Australian cohort data.

Aims: To determine median life years lost, all-cause standardised mortality ratio (SMR) and cause-specific SMR, their predictors and secular change in Australian patients with RA.

Methods: Study population was all patients seen by a rheumatologist between 1990 and 1994. Record linkage with Australian National Death Index was performed to determine fact and cause of death up to 2004. All-cause and cause-specific SMR, and median life years lost were determined.

Results: There were 35 (31%) deaths in the early 1990s cohort (n = 113), SMR 1.31 (95% 0.93, 1.80). There were 216 (44%) deaths in the pre-1990s established cohort (n = 495), SMR 1.73 (1.49, 1.95). Median life years lost in the early cohort was 6 years for males and 7 years for females compared with 8 and 10 years, respectively, in the established cohort. Patients with low disease activity score at baseline (DAS < 3.2), SMR was 0.8 (0.3, 2.2) and 1.5 (1.1, 2.2) for the early and established cohorts, and if DAS ≥3.2, SMR was 1.4 (1.02, 1.98) and 1.8 (1.5, 2.1) respectively. Primary cause of death was cardiovascular disease (SMR 1.43 (1.17, 1.74). Patients at most risk were those age 45-54 years. RA was listed as a comorbid condition on the death certificate in only 16% of patients.

Conclusions: Within a period of 14 years, median life expectancy of patients with RA with disease onset in the early 1990s is reduced by 6-7 years. However, our results also suggest a secular reduction in excess mortality.

Citing Articles

Investigating the causal relationship between rheumatoid arthritis and cardiovascular disease: A Mendelian randomization study.

Xie X, Wei G, Tang Z, Chen H, Lin X, Huang C Clin Rheumatol. 2025; 44(3):1057-1067.

PMID: 39909965 DOI: 10.1007/s10067-025-07357-4.


Janus kinase inhibitors versus tumor necrosis factor inhibitors in rheumatoid arthritis: meta-analytical comparison of efficacy and safety.

Kandeel M, Morsy M, Alkhodair K, Alhojaily S Inflammopharmacology. 2024; 32(5):3229-3246.

PMID: 39217589 DOI: 10.1007/s10787-024-01563-3.


Association between rheumatoid arthritis and serum vitamin C levels in Adults: Based on the National health and Nutrition Examination survey database.

Zhang J, Liu P, Huang S, Chen Q, Wang X, Liu H Prev Med Rep. 2024; 44:102793.

PMID: 38979480 PMC: 11228779. DOI: 10.1016/j.pmedr.2024.102793.


Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials.

Cai W, Tong R, Sun Y, Yao Y, Zhang J Front Pharmacol. 2024; 15:1387585.

PMID: 38725657 PMC: 11080655. DOI: 10.3389/fphar.2024.1387585.


Implementing a Staff-Led Smoking Cessation Intervention in a Diverse Safety-Net Rheumatology Clinic: A Pre-Post Scalability Study in a Low-Resource Setting.

Brandt J, Ramly E, Lim S, Bao G, Messina M, Piper M Arthritis Care Res (Hoboken). 2024; 76(9):1342-1350.

PMID: 38622089 PMC: 11349476. DOI: 10.1002/acr.25349.